The FDA placed on hold a Phase I/II clinical study evaluating Advaxis' ADXS11-001, or axalimogene filolisbac, in combination with AstraZeneca's Imfinzi, or durvalumab, after a patient died of respiratory failure. The study is assessing the combination in patients with HPV-associated head and neck cancer, as well as patients with advanced, recurrent or refractory HPV-associated cervical cancer.

Related Summaries